Superworth

Relay Therapeutics price to book ratio RLAY

Market value divided by the book value of the company's net assets, since 2020.

Today, Nov 2, 2026
4.3×
6-year median
2.2×
Against its 6-year history
77th
percentile: 0 is its lowest day, 100 its highest
6-year range
0.4× to 7.8×
Peer median
5.8×

Relay Therapeutics' price to book ratio is 4.3× as of Nov 2, 2026.

That is above its 6-year median of 2.2×, higher than on 77% of days in the last 6 years.

Over that time it ranged from 0.4× in Apr 2025 to 7.8× in Jan 2021.

The median for 10 biotech stocks of a similar size is 5.8×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far4.3×2.1×6.0×
20252.4×0.4×2.4×
20240.9×0.8×1.8×
20231.7×0.9×2.7×
20221.8×1.8×5.1×
20215.8×3.5×7.8×
20205.2×5.2×6.7×

Against its peers

Companies in Biotechnology nearest Relay Therapeutics' size, closest first, today.

CompanyPrice to book ratio
RLAYRelay Therapeutics4.3×
ADMAAdma Biologics6.1×
VCELVericel5.6×
KRYSKrystal Biotech6.4×
RGENRepligen4.6×
TECHBIO-TECHNE5.4×
HALOHalozyme Therapeutics102×
NBIXNeurocrine Biosciences4.0×
MGTXMeiraGTx4.2×
EXELExelixis9.4×
ALNYAlnylam Pharmaceuticals15.7×
Peer median5.8×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Relay Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.